On Feb. 5, the Trump administration launched TrumpRx, a new digital platform designed to help Americans navigate the often-crushing costs of prescription drugs. While President Trump has called the initiative “one of the most transformative health care initiatives of all time,” a recent BlackDoctor survey of more than 250 respondents, suggests that TrumpRx is being met with a heavy dose of skepticism in the Black community. In fact, more than 62 percent of respondents said that they were “very unlikely” to use the direct-to-consumer platform.
At its core, TrumpRx is the administration’s answer to the pharmacy counter “sticker shock” many families face. The website features dozens of medications — including high-demand treatments for weight loss, diabetes, and fertility—at prices listed far below their standard rates.
Major pharmaceutical companies, such as Pfizer and Novo Nordisk, are on board. For instance, the popular GLP-1 weight-loss injection Wegovy, which normally carries a list price of $1,349, is listed on TrumpRx for $199 for the first two months and $349 thereafter. (It is worth noting that Novo Nordisk has recently offered similar discounts through its own channels). Additionally, Gonal-F, a vital drug for families undergoing IVF, is listed at $252 per unit – an 83% discount.
However, there are several important things to know, for instance, TrumpRx doesn’t actually sell you the medicine. Instead, it’s a tool where you print a coupon to bring to your local pharmacy.
In a recent BlackDoctor exclusive interview, Shantel Houston, Pharma, Interim Executive VP of the National Pharmaceutical Association, said “There is a significant catch [to TrumpRx]. Many of the manufacturer coupons featured on TrumpRx are unavailable to people enrolled in Medicare or Medicaid. This excludes a large portion of Black seniors and low-income individuals who rely on those programs.”
Related Article: Will TrumpRX Actually Lower Drug Costs? The Head of the National Pharmaceutical Association Breaks it Down for Us
While the list of drugs is reportedly going to grow, many health experts worry that the site might not actually change the bottom line for the average person.
BlackDoctor launched a survey of its audience in late February 2026 to gauge its audience’s perception of the program. The findings* highlight a deep disconnect between the government’s goals and the community’s trust.
The Choice: If you have a chronic condition, “self-pay” options, like TrumpRx, can be a double-edged sword. Any money you spend using these coupons typically does not count toward your insurance deductible. For many, that could be a non-starter.
The Context: There are over 24,000 FDA-approved drugs, but TrumpRx currently only covers 43. In addition, 90% of prescriptions in the U.S. are generics. For some drugs, the generic version is often already cheaper at the pharmacy than the “discounted” brand-name price on the TrumpRx site.
The Math: The vast majority of BlackDoctor community members who responded to the survey have traditional insurance. This mirrors data from KFF, which shows that 66% of people under 65 have private insurance. For these consumers, a $30 insurance copay is usually a much better deal than a $98.84 “discounted” price on a website.
The Competition: Established online prescription discount names, like GoodRx and Mark Cuban’s Cost Plus Drug Company, offer a massive selection compared to TrumpRx and have a longer track record. That said, many insured people only switch to these tools if they are facing a high deductible they haven’t met yet.
The Barriers: The most striking finding is the profound lack of trust. In addition, the site is an aggregator rather than a direct seller, so it doesn’t always show the full picture. Experts warn that without seeing side-by-side generic costs, some patients might inadvertently pay more through TrumpRx than they would by simply using their insurance.
While TrumpRx promises to bring “Most-Favored-Nation” pricing to the U.S., 2 out of 3 BlackDoctor readers surveyed simply don’t trust it. As Houston recommends, “Do your research” and weigh your options.
*These results are based on a sample of 250 participants surveyed between Feb. 20 and Feb. 24. For a sample of this size, the margin of error is approximately ±6.2% at a 95% confidence level.
By subscribing, you consent to receive emails from BlackDoctor.com. You may unsubscribe at any time. Privacy Policy & Terms of Service.
